Nanoparticle formulations of cisplatin for cancer therapy.
Nanoparticle formulations of cisplatin for cancer therapy.
复制标题
DOI：
10.1002/wnan.1390
复制
发表时间：
2016-09
期刊：
影响因子：
--
通讯作者：
Lin W
中科院分区：
文献类型：
--
作者：
Duan X;He C;Kron SJ;Lin W
基因毒性剂顺铂，单独使用或与放射和/或其他化疗剂联合使用，是广泛癌症的重要一线化疗。顺铂的临床应用受到内在和获得性耐药性以及剂量限制性正常组织毒性的限制。顺铂对肿瘤和正常组织的选择性很小，这可能是限制其价值的关键因素。为了克服游离药物的低治疗率，已经探索了大分子、脂质体和纳米颗粒药物递送系统，以利用增强的渗透性和保留（EPR）效应并促进顺铂向肿瘤的递送。在这里，我们调查顺铂的纳米颗粒制剂的最新进展，专注于在临床前或临床环境中显示前景的药物。
The genotoxic agent cisplatin, used alone or in combination with radiation and/or other chemotherapeutic agents, is an important first-line chemotherapy for a broad range of cancers. The clinical utility of cisplatin is limited both by intrinsic and acquired resistance and dose-limiting normal tissue toxicity. That cisplatin shows little selectivity for tumor versus normal tissue may be a critical factor limiting its value. To overcome the low therapeutic ratio of the free drug, macromolecular, liposomal and nanoparticle drug delivery systems have been explored toward leveraging the enhanced permeability and retention (EPR) effect and promoting delivery of cisplatin to tumors. Here, we survey recent advances in nanoparticle formulations of cisplatin, focusing on agents that show promise in preclinical or clinical settings.